Founded in 2015, Qynapse is on a mission to advance the accuracy and reliability of central nervous diseases (CNS) screening and monitoring in both clinical routine settings and in clinical trial applications.
Headquartered in France with teams in the United States and in Canada, the Qynapse team is dedicated to building cloud-based software that analyzes brain images and other markers of neurodegeneration to create the most accurate and reliable predictors and objective measures of CNS disorders, such as Alzheimer’s disease, Multiple Sclerosis and Parkinson’s disease.
Powered by proprietary Artificial Intelligence, our solution QyScore® produces a wide range of automated neuroimaging biomarkers to assist physicians making clinical care decisions and monitoring patients over time. QyPredict®, our predictive technology, is being designed to transform what we know about CNS disease trajectory to impact clinical trial design and outcomes.
Together, we are moving forward to a brighter and more accurate future of diagnosis and treatment for central nervous system diseases.